Process and Outcome Evaluation of Different Psychotherapies
Process and Outcome Evaluation of Psychotherapeutic Approaches At the Outpatient Clinic for Psychotherapy of the Paris Lodron University Salzburg
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Salzburg, Austria, 5020
- Paris-Lodron-University Salzburg
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients: indication for psychotherapy, adult patients capable of giving consent, with sufficient knowledge of German to complete the questionnaires, signed treatment contract and declaration of consent
- Psychotherapists: officially registered psychotherapists and psychotherapists in training under supervision (in Austria), signed work contract and declaration of consent
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
psychoanalytic-psychodynamic therapy
|
Patients are assigned to a therapist and will receive psychotherapy
|
|
humanistic therapy
|
Patients are assigned to a therapist and will receive psychotherapy
|
|
systemic therapy
|
Patients are assigned to a therapist and will receive psychotherapy
|
|
cognitive-behavioral therapy
|
Patients are assigned to a therapist and will receive psychotherapy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hopkins Symptom Checklist Short Form (HSCL-11)
Time Frame: through study completion, an average of 1 year
|
11 items, Likert scale: 4-point scale; 1 (not at all) to 4 (very much), Minimum value: 11, Maximum value: 44, Higher scores indicate more mental health problems.
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Health Questionnaire-8 (PHQ-8)
Time Frame: through study completion, an average of 1 year
|
8 items, Likert scale: 4-point; 0 (not at all) to 3 (nearly every day), Minimun value: 0, Maximum value: 24, Higher scores indicate more depressive symptoms, Score ≥ 10 indicate depression.
|
through study completion, an average of 1 year
|
|
Generalizied Anxiety Disorder Scale-7 (GAD-7)
Time Frame: through study completion, an average of 1 year
|
7 items, Likert scale: 4-point; 0 (not at all) to 3 (nearly every day), Minimun value: 0, Maximum value: 21, Higher scores indicate more anxiety symptoms, Score ≥ 10 indicate anxiety.
|
through study completion, an average of 1 year
|
|
Patient Health Questionnaire-4 (PHQ-4)
Time Frame: through study completion, an average of 1 year
|
4 items, Likert scale: 4-point; 0 (not at all) to 3 (nearly every day), Minimun value: 0, Maximum value: 12, Higher scores indicate more depressive and anxiety symptoms, Score ≥3 for first 2 questions indicates depression, Score ≥ 3 for last 2 questions indicates anxiety.
|
through study completion, an average of 1 year
|
|
Positive Mental Health scale (PMH)
Time Frame: through study completion, an average of 1 year
|
9 items, Likert skala: 4-point; 0 (do not agree) to 3 (agree), Minimun value: 0, Maximum value: 27, Higher scores indicate higher positive mental health.
|
through study completion, an average of 1 year
|
|
Society for Psychotherapy Research Item on Mental Health
Time Frame: through study completion, an average of 1 year
|
1 item, Likert scale: 5-point; 0 (very bad) to 4 (very good), Minimum value: 0, Maximum value: 4, Higher scores indicate better mental health.
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Thomas Probst, Univ.Prof.Dr, Paris-Lodron-University Salzburg
- Principal Investigator: Franziska Pfannerstill, Dr., Paris-Lodron-University Salzburg
- Principal Investigator: Hannah van Alebeek, Dr., Paris-Lodron-University Salzburg
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 14/2024
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.